2010
DOI: 10.1016/j.vaccine.2010.04.028
|View full text |Cite
|
Sign up to set email alerts
|

OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(29 citation statements)
references
References 18 publications
0
29
0
Order By: Relevance
“…These results suggested that OprF is a host immune system sensor, modulating QS to enhance virulence when the bacteria are in contact with the host. Very interestingly, sera from OprF/I fusion protein-vaccinated humans inhibited P. aeruginosa binding to gamma interferon, suggesting a novel mechanism in which blocking of gamma interferon binding abrogates the virulence enhancement of P. aeruginosa, thereby contributing to efficient host defense against P. aeruginosa infection (24). In our experiments, no gamma interferon was present and the absence of OprF still reduced the QS network activity, indicating that OprF might sense signals other than gamma interferon.…”
Section: Vol 79 2011mentioning
confidence: 52%
“…These results suggested that OprF is a host immune system sensor, modulating QS to enhance virulence when the bacteria are in contact with the host. Very interestingly, sera from OprF/I fusion protein-vaccinated humans inhibited P. aeruginosa binding to gamma interferon, suggesting a novel mechanism in which blocking of gamma interferon binding abrogates the virulence enhancement of P. aeruginosa, thereby contributing to efficient host defense against P. aeruginosa infection (24). In our experiments, no gamma interferon was present and the absence of OprF still reduced the QS network activity, indicating that OprF might sense signals other than gamma interferon.…”
Section: Vol 79 2011mentioning
confidence: 52%
“…OprF is highly conserved in pseudomonads, allowing the passage of small molecules across the outer membrane, and has been studied extensively as a vaccine candidate (15,35,36). Porins have also been described as acceptor molecules for C3b in Salmonella enterica serovar Typhimurium, Klebsiella pneumoniae, Neisseria meningitidis, and Legionella pneumophila (28,(37)(38)(39).…”
Section: Discussionmentioning
confidence: 99%
“…Understanding the molecular mechanism of C3 binding to bacterial surfaces offers a potential means for preventing and/or treating diseases caused by these Gram-negative pathogens. Moreover, since C3b binding to proteins greatly facilitates antigen presentation by antigen-presenting cells (50), C3b binding to OprF may be one mechanism whereby OprF serves as a potent vaccine (36,51).…”
Section: Figmentioning
confidence: 99%
“…150 In a recent study it was demonstrated that OprF-OprI vaccinated sera from human volunteers inhibit P. aeruginosa binding to IFNγ, suggesting an additional effector mechanism of OprF containing vaccines. 151 OprI was demonstrated to adhere to the mucosal surfaces of the respiratory and intestinal tract and may so act as a mucosal carrier to facilitate antigen delivery to antigenpresenting cells. 152 In addition to conventionally extracted or recombinant protein preparations, Opr have been successfully tested in several other formulations including DNA vaccines, 129,130 peptide vaccine, 153 viral vectors, 154-159 dendritic cell-pulsed, 160 or heterologously expressed in bacterial vectors.…”
Section: Type III Secretion System Extracellular Toxins and Proteasesmentioning
confidence: 99%